[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Apellis Pharmaceuticals Inc (APLS)

Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,252,701
  • Shares Outstanding, K 128,021
  • Annual Sales, $ 1,004 M
  • Annual Income, $ 22,390 K
  • EBIT $ 55 M
  • EBITDA $ 59 M
  • 60-Month Beta -0.24
  • Price/Sales 5.23
  • Price/Cash Flow 196.23
  • Price/Book 14.02

Options Overview Details

View History
  • Implied Volatility 3.12% (-4.92%)
  • Historical Volatility 243.40%
  • IV Percentile 1%
  • IV Rank 0.16%
  • IV High 97.27% on 07/28/25
  • IV Low 2.97% on 05/04/26
  • Expected Move (DTE 4) 0.04 (0.10%)
  • Put/Call Vol Ratio 11.12
  • Today's Volume 824
  • Volume Avg (30-Day) 721
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 44,729
  • Open Int (30-Day) 47,201
  • Expected Range 41.00 to 41.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.35
  • Number of Estimates 11
  • High Estimate $-0.16
  • Low Estimate $-0.49
  • Prior Year $-0.33
  • Growth Rate Est. (year over year) -6.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.70 +0.81%
on 04/13/26
41.14 -0.27%
on 05/06/26
+0.24 (+0.59%)
since 04/10/26
3-Month
16.83 +143.79%
on 03/30/26
41.14 -0.27%
on 05/06/26
+18.72 (+83.91%)
since 02/11/26
52-Week
16.10 +154.84%
on 05/15/25
41.14 -0.27%
on 05/06/26
+23.73 (+137.17%)
since 05/09/25

Most Recent Stories

More News
Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

NEW YORK , May 7, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the opening of trading on Thursday, May 14:

RELY : 24.52 (+2.04%)
APLS : 41.04 (+0.02%)
SPGI : 421.06 (+0.22%)
TPH : 46.97 (+0.04%)
BIIB : 197.50 (+2.09%)
BFAM : 69.15 (-2.04%)
Apellis Has Spent a Year Preparing Investors for This Report

Barchart Research What to Expect from APLS Earnings APLS Generated May 5, 2026 Current Price $40.97 EPS Estimate $$-0.38 Consensus Rating Hold Average Move 10.02% Apellis Has Spent a Year Preparing Investors...

APLS : 41.04 (+0.02%)
Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Apellis Pharmaceuticals...

APLS : 41.04 (+0.02%)
BIIB : 197.50 (+2.09%)
Are GSAT, APLS, FORA Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

APLS : 41.04 (+0.02%)
FORA : 2.17 (+0.70%)
GSAT : 82.20 (+0.13%)
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

KZR : 7.29 (-0.95%)
CNTA : 39.58 (-0.03%)
APLS : 41.04 (+0.02%)
SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger--KZR, CNTA, AFBI, and APLS

NEW YORK , April 8, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of...

AFBI : 22.45 (-0.04%)
KZR : 7.29 (-0.95%)
CNTA : 39.58 (-0.03%)
APLS : 41.04 (+0.02%)
Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

KORE : 9.15 (+0.11%)
CNTA : 39.58 (-0.03%)
APLS : 41.04 (+0.02%)
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)

NEW YORK , April 1, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

APLS : 41.04 (+0.02%)
Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Apellis Pharmaceuticals...

APLS : 41.04 (+0.02%)
BIIB : 197.50 (+2.09%)
Stocks Surge on Signs the US and Iran Seek to End War

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +2.91%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +2.49%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +3.43%. June E-mini...

ALK : 39.11 (-4.24%)
GOOGL : 389.66 (-2.78%)
AAPL : 292.10 (-0.32%)
SNDK : 1,550.50 (-0.76%)
ADI : 419.95 (+0.82%)
CNTA : 39.58 (-0.03%)
OXY : 55.10 (+3.90%)
TSLA : 445.34 (+3.97%)
STX : 833.21 (+6.46%)
WDC : 516.67 (+7.64%)
SPY : 738.30 (+0.09%)
META : 598.72 (-1.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Apellis Pharmaceuticals, Inc. is a clinical-stage biotech focused on the development of novel therapeutics, which work through the inhibition of the complement system, specially targeting the C3 protein of the complement system to treat autoimmune and inflammatory diseases.

See More

Key Turning Points

3rd Resistance Point 41.10
2nd Resistance Point 41.08
1st Resistance Point 41.05
Last Price 41.04
1st Support Level 41.00
2nd Support Level 40.98
3rd Support Level 40.95

See More

52-Week High 41.14
Last Price 41.04
Fibonacci 61.8% 31.57
Fibonacci 50% 28.62
Fibonacci 38.2% 25.67
52-Week Low 16.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.